Cultivecs Inc. plans to start manufacturing antibody drugs from 2018 at newly-built manufacturing plant in correspondence with Japanese, US, European standards in the location of Niigata Factory of Mitsubishi Gas Chemical Co., Inc. It is planned to introduce single-use equipment almost over the processes from the culturing process to the purification process.
We will introduce 1,000 L scale bioreactor (Xcellerex XDR Single-Use Bioreactor；GE Healthcare) firstly and keep a space for subsequent expansion to 2,000 L scale bioreactor and purification system to meet demand.
Not only to respond to requests from clients, we will also plan new projects and product by ourselves and propose them to potential partner companies for us.
Under the deep relationship we are confident to provide our partner companies with wide-range one-stop service from initial process development, GMP manufacturing, clinical trials up to development strategy of products.